long intergenic non-protein coding RNA 1894Genealiases: []
Q-omics provides the consensus-scored LINC01894 profile across patient tissues and cancer cell-line models. LINC01894 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC01894 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, LINC01894 RNA expression shows 12,040 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, COAD, and PDAC as cancer lineages where LINC01894 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01894 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01894 survival associations across molecular data types. LINC01894 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01894 RNA expression–survival associations across cancer types. High LINC01894 expression shows unfavorable associations in ACC, KIRP, THCA and LGG, but favorable associations in UCS and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify ACC as the clearest survival context for LINC01894 RNA expression.
This table summarizes LINC01894 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01894. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01894 shows lower tumor expression in COAD, BRCA, UCEC, HNSC, KIRC and STAD. The COAD box plot shows higher LINC01894 RNA expression in normal versus tumor tissue (log2 FC = −0.144, t-test p = .005).
This table shows molecular features associated with LINC01894 in patient tissues and cancer cell lines. In patient samples, LINC01894 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
